𝔖 Bobbio Scriptorium
✦   LIBER   ✦

Prognostic significance of the immunohistochemical expression of O6-methylguanine-DNA methyltransferase, P-glycoprotein, and multidrug resistance protein-1 in glioblastomas

✍ Scribed by Takao Nakagawa; Kazunori Ido; Takahiro Sakuma; Hiroaki Takeuchi; Kazufumi Sato; Toshihiko Kubota

Book ID
108958115
Publisher
John Wiley and Sons
Year
2009
Tongue
English
Weight
436 KB
Volume
29
Category
Article
ISSN
0919-6544

No coin nor oath required. For personal study only.

πŸ“œ SIMILAR VOLUMES

Expression of DNA repair proteins hMSH2,
Expression of DNA repair proteins hMSH2, hMSH6, hMLH1, O6-methylguanine-DNA methyltransferase and N-methylpurine-DNA glycosylase in melanoma cells with acquired drug resistance
✍ Hermann Lage; Markus Christmann; Monika A. Kern; Manfred Dietel; Matthias Pick; πŸ“‚ Article πŸ“… 1999 πŸ› John Wiley and Sons 🌐 French βš– 157 KB

Malignant melanoma is well known for its primary unresponsiveness to chemotherapy. The mechanisms conferring this intrinsic resistance are unclear. In this study, we investigated the role of genes involved in DNA repair in a panel of human melanoma cell variants exhibiting low and high levels of res

Inactivation of the DNA repair gene O6-m
Inactivation of the DNA repair gene O6-methylguanine-DNA methyltransferase by promoter hypermethylation and its relationship to aflatoxin B1-DNA adducts and p53 mutation in hepatocellular carcinoma
✍ Yu-Jing Zhang; Yu Chen; Habibul Ahsan; Ruth M. Lunn; Po-Huang Lee; Chien-Jen Che πŸ“‚ Article πŸ“… 2002 πŸ› John Wiley and Sons 🌐 French βš– 237 KB πŸ‘ 1 views

## Abstract O^6^‐methylguanine‐DNA methyltransferase (MGMT) is a repair protein that specifically removes promutagenic alkyl groups from the O^6^ position of guanine in DNA. __MGMT__ is transcriptionally silenced by promoter hypermethylation in several human cancers. Methylation‐specific PCR (MSP)

The P140K mutant of human O6-methylguani
The P140K mutant of human O6-methylguanine-DNA-methyltransferase (MGMT) confers resistance in vitro and in vivo to temozolomide in combination with the novel MGMT inactivator O6-(4-bromothenyl)guanine
✍ Lorna B. Woolford; Thomas D. Southgate; Geoffrey P. Margison; Michael D. Milsom; πŸ“‚ Article πŸ“… 2005 πŸ› John Wiley and Sons 🌐 English βš– 155 KB

The O 6 -methylguanine-DNA-methyltransferase (MGMT) inactivator O 6benzylguanine (O 6 -beG) is currently under clinical investigation as a potential tumour-sensitising agent. In clinical trials its use has been associated with increased myelotoxicity and a reduced maximum tolerated dose (MTD) for BC